bioAffinity Technologies (BIAF) vs. Its Rivals Critical Analysis

bioAffinity Technologies (NASDAQ:BIAF) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare bioAffinity Technologies to similar companies based on the strength of its institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Volatility and Risk

bioAffinity Technologies has a beta of 3.93, indicating that its stock price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ competitors have a beta of 5.57, indicating that their average stock price is 457% more volatile than the S&P 500.

Valuation and Earnings

This table compares bioAffinity Technologies and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-2.88
bioAffinity Technologies Competitors	$1.55 billion	$101.44 million	0.11

bioAffinity Technologies’ competitors have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 16.7% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares bioAffinity Technologies and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-249.68%	-18.81%	-11.37%

Analyst Recommendations

This is a summary of current ratings for bioAffinity Technologies and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	50	817	1300	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 7.06%. Given bioAffinity Technologies’ competitors higher probable upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its competitors.

Summary

bioAffinity Technologies competitors beat bioAffinity Technologies on 9 of the 10 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.